ketamine, deschloroketamine, methoxetamine +1 moreketamine, deschloroketamine, methoxetamine, phencyclidine show less
2-Fluorodeschloroketamine
2-FDCK (2-fluorodeschloroketamine) — also known as fluoroketamine — is a synthetic dissociative of the arylcyclohexylamine class.[1] It is a close structural analog of ketamine, with a single fluorine atom replacing the chlorine in ketamine's structure. It blocks glutamate signaling in the brain,[2] producing the detachment from body and environment that defines dissociative experiences.
2-FDCK (2-fluorodeschloroketamine) is an emerging synthetic dissociative of the arylcyclohexylamine class. It is a close structural analog of ketamine, distinguished by a fluorine-for-chlorine swap and a somewhat longer duration.[1] 2-FDCK is a presumed NMDA receptor antagonist, producing its effects by blocking glutamate signaling at ion channels throughout the brain.[2]
ketamine, deschloroketamine, methoxetamine +1 moreketamine, deschloroketamine, methoxetamine, phencyclidine show less
First synthesized in 1987 as an anesthetic candidate,[3] 2-FDCK attracted no scientific interest for nearly three decades. It appeared on research chemical markets around 2015 as a legal substitute for ketamine and spread to at least 13 countries.[1][2] The UN placed it in Schedule II in March 2024,[4] and the US DEA moved it to Schedule I in February 2026.[5]
Subjective effects include dissociation, cognitive softening, perceptual distortion, time alteration, and analgesia. The experience builds gradually — a warm, layered disconnection from body and environment, more gentle in onset than Ketamine, though deep hole states remain possible at higher doses. Nausea, confusion, agitation, and a residual cognitive heaviness are the most common unwanted effects.
2-FDCK produces clinical dependence with chronic daily use,[6] and its toxicity is shaped primarily by cardiovascular stimulation and respiratory risk. Every documented fatality involved polydrug combinations — other depressants compound its sedating effects and can stop breathing entirely.[7][8] No human pharmacokinetic studies and no controlled trials exist — understanding rests entirely on structural analogy to ketamine and forensic case reports.[1][2]
History[edit]
Discovery
2-FDCK was first synthesized in 1987 by Wang S-y at Peking University as part of a search for fluorinated anesthetic compounds.[3] No pharmacological testing followed, and the compound was forgotten for nearly three decades. A new synthesis route published in 2014 provided the blueprint for later production.[9]
Market Emergence
2-FDCK appeared on online research chemical markets around 2015, marketed as a legal ketamine replacement.[1][2] By 2023 it had been detected in wastewater, drug seizures, or clinical cases across at least 13 countries.[2][10][11]
International Scheduling
The WHO recommended Schedule II placement in October 2023,[2] implemented by the UN Commission on Narcotic Drugs in March 2024.[4] The US DEA placed it in Schedule I effective February 2026.[5]
The name "2-FDCK" reflects its structural relationship to deschloroketamine — the "2-F" indicating fluorine at the 2-position of the phenyl ring.[1] It is also sold as 2F-DCK and fluoroketamine. Its rapid spread follows the typical research chemical pattern: a near-copy of a scheduled drug, sold under a chemical name, until it too is controlled.
Chemistry[edit]
Structural Class
2-FDCK belongs to the arylcyclohexylamine class — the same chemical family as ketamine, phencyclidine, and deschloroketamine.[1] Its molecular formula is C₁₃H₁₆FNO.
The only structural difference from ketamine is a single fluorine atom in place of chlorine — a swap predicted to alter how quickly the liver metabolizes it.[12]
Pharmacology[edit]
Mechanism of Action
No published binding data exist for 2-FDCK at any molecular target.[1][2] It is presumed to block glutamate signaling — the same mechanism as ketamine — based on its nearly identical structure and on animal studies showing shared behavioral effects.[13]
Like other drugs in its structural class, 2-FDCK also weakly inhibits dopamine reuptake.[14][1] This contributes to the mildly stimulating quality that distinguishes arylcyclohexylamines from purely sedating dissociatives.
Pharmacokinetics
The body breaks 2-FDCK down mainly by stripping a methyl group from its nitrogen, producing the primary metabolite nor-2F-DCK.[6][15][16] Deschloroketamine is also produced as a metabolite — so a positive DCK result in drug testing may reflect 2-FDCK use, not DCK itself.[6] Oral doses are substantially weakened by first-pass liver metabolism before reaching the bloodstream.[17]
Neuroscience[edit]
Where It Acts
2-FDCK is presumed to disrupt the brain's sensory relay — the communication between the thalamus and the cortex that stitches sensory input into a continuous sense of self and environment.inferred This disruption weakens the feeling of being grounded in the body and in the present moment.
Why It Matters
Blocking glutamate signaling silences inhibitory neurons, which triggers a surge of excitatory glutamate that briefly drives new synaptic connections.inferred This is the same mechanism behind ketamine's rapid antidepressant effect, and preclinical data show 2-FDCK triggers the same molecular changes in reward circuits.[18]
Subjective Effects[edit]
The 2-FDCK experience builds gradually into a warm, layered dissociation. Perception shifts without arriving abruptly, and the sense of being grounded in the body loosens slowly. At higher doses, that loosening deepens into full disconnection from body and surroundings.
Within the dissociative class, 2-FDCK sits between ketamine and deschloroketamine in character. It is gentler and longer-lasting than Ketamine, with a smoother onset. It is shorter-acting and less sedating than DCK, with a cleaner return to baseline.
First synthesized in 1987 as a fluorinated anesthetic candidate,[3] 2-FDCK attracted no pharmacological interest for nearly three decades. It surfaced on research chemical markets around 2015–2016 as a legal ketamine substitute and has since been detected across at least 13 countries.[2] The UN Commission on Narcotic Drugs placed it in Schedule II in March 2024,[4] and the US DEA temporarily scheduled it in Schedule I effective February 2026.[5]
Subjective effects include dissociation, cognitive disconnection, perceptual distortion, analgesia, and time alteration. The experience is often described as a gentler, more gradual version of ketamine — a warm cognitive softening that builds in layers rather than arriving abruptly, while retaining the capacity for deep dissociative states at higher doses. Nausea (particularly with oral use), confusion, agitation, and residual cognitive heaviness are common unsought effects.
Preclinical studies demonstrate abuse liability comparable to ketamine,[6][7] and clinical dependence with chronic daily use has been documented.[8] All recorded fatalities have involved polydrug combinations — particularly other depressants — where additive respiratory depression narrows the survival margin;[9][10] chronic use raises concern for bladder damage analogous to ketamine cystitis, though this remains unstudied. No binding affinity data, no human pharmacokinetic studies, and no controlled trials exist — the current understanding rests entirely on structural analogy to ketamine, animal models, and forensic case reports.[1][2]
History[edit]
Discovery
2-FDCK was first synthesized in 1987 by Wang S-y and Li C-x at Peking University as part of a structure-activity investigation into fluorinated ketamine analogues intended as anesthetic candidates.[3] No pharmacological evaluation accompanied the synthesis, and the compound attracted no further scientific attention for nearly three decades. A modern synthesis route published by Moghimi et al. in 2014 became the primary reference for subsequent production.[11]
Market Emergence
2-FDCK appeared on online research chemical markets around 2015 and was formally notified to the European Monitoring Centre for Drugs and Drug Addiction in 2016, marketed as a "legal replacement for ketamine".[1][2] Wastewater analysis confirmed population-level recreational use in Guangzhou, China, by 2018,[12] and clinical presentations followed in Hong Kong (2019)[13] and the United States (2021).[14] By 2023, the compound had been detected in wastewater, drug seizures, or clinical cases across at least 13 countries.[2][15][16]
International Scheduling
The WHO Expert Committee on Drug Dependence recommended placement of 2-FDCK in Schedule II of the 1971 Convention on Psychotropic Substances in October 2023,[2] implemented by the Commission on Narcotic Drugs in March 2024.[4] The US DEA announced temporary Schedule I placement in January 2026, effective February 19, 2026.[5]
The name "2-FDCK" derives from its structural relationship to deschloroketamine (DCK) — the "2-F" prefix indicating the fluorine substitution at the 2-position of the phenyl ring. The compound is also known as 2F-DCK and fluoroketamine in research chemical markets.[1] Its rapid spread exemplifies the analogue-market dynamic in which novel psychoactive substances are synthesized as near-copies of scheduled drugs, marketed under chemical nomenclature, and replaced by newer analogues once controlled.
Chemistry[edit]
Structural Class
2-FDCK belongs to the arylcyclohexylamine class, defined by a cyclohexane ring bonded to both an aryl group and an amine. The class includes ketamine, phencyclidine, methoxetamine, and deschloroketamine. 2-FDCK shares ketamine's exact molecular scaffold, differing only by the substitution of fluorine for chlorine at the ortho position of the phenyl ring.[1]
Fluorine is smaller and more electronegative than chlorine, which alters the electronic distribution across the phenyl ring and is predicted to influence both receptor binding geometry and hepatic clearance rate.[17]
Molecular Properties
| Molecular formula | C₁₃H₁₆FNO |
| Molecular weight | 221.27 g/mol |
The compound contains a cyclohexanone ring with a carbonyl group at C-1, a secondary amine (methylamino) at C-2, and a 2-fluorophenyl group also at C-2, creating a quaternary carbon center.
Stereochemistry
The carbon bearing both the aryl group and the methylamino substituent is a chirality center, making 2-FDCK a chiral molecule. It is encountered as a racemic mixture (equal mix of R and S forms). No data characterize the relative potency of the individual enantiomers.[1][2]
By analogy to ketamine — where the S-enantiomer is roughly four times more potent at the NMDA — the S form of 2-FDCK may carry most of the activity, but this remains unconfirmed.
Physical Properties
The hydrochloride salt appears as a white crystalline powder. Detailed characterization data (melting point, solubility, pKa) have not been published. Forensic analyses of seized samples have found purity levels of 67% and 96%, with trace deschloroketamine contamination (0.4–0.6%).[8]
Pharmacology[edit]
Mechanism of Action
No published binding affinity data exist for 2-FDCK at any molecular target.[1][2] All mechanistic understanding is inferred from structural analogy to ketamine and from behavioral studies in animals. The WHO Critical Review states that "the mechanism remains uncertain" and that effects mirror those of NMDA receptor antagonists.[2]
NMDA receptor antagonism is the presumed primary mechanism. Ketamine blocks NMDA receptors by entering the open ion channel and lodging in the phencyclidine binding site. 2-FDCK preserves the complete ketamine scaffold with only a fluorine-for-chlorine swap, strongly predicting conservation of this action. Drug discrimination studies confirm the inference: 2-FDCK fully substituted for ketamine in trained rats at a comparable dose, consistent with shared NMDA-mediated effects.[6]
Dopamine reuptake inhibition is inferred as a secondary mechanism. Arylcyclohexylamines as a class inhibit dopamine reuptake, contributing to their mildly stimulating and reinforcing qualities.[18][1]
Sigma receptor activity is inferred as a tertiary mechanism. Ketamine binds sigma receptors at moderate concentrations,[19] and this property may contribute to dissociative phenomenology. No sigma binding data for 2-FDCK have been published.
Pharmacokinetics
No controlled human pharmacokinetic studies exist for 2-FDCK. Available data derive from forensic samples, liver microsome experiments, and computational modeling.
Hepatic clearance ranks between ketamine (faster) and deschloroketamine (slower), with the fluorine substitution predicted to yield moderately faster liver metabolism than DCK but slower clearance than ketamine itself.[17]
The primary metabolic pathway is N-demethylation to nor-2F-DCK, the main metabolite detected across all published human studies.[8][13][20] Additional pathways include carbonyl reduction (producing dihydro-2F-DCK), hydroxylation, and glucuronidation. A forensically important finding: deschloroketamine (DCK) is a metabolite of 2-FDCK — a positive DCK result in forensic testing may reflect 2-FDCK metabolism rather than direct DCK consumption.[8]
Oral bioavailability is expected to be substantially reduced by first-pass liver metabolism, as it is for ketamine (approximately 17–29%).[21] The dose disparity between oral and insufflated routes in community reports is consistent with significant first-pass loss.inferred
Neuroscience[edit]
Where It Acts
As a presumed NMDA receptor antagonist, 2-FDCK is expected to disrupt communication between the thalamus and cortex — the relay system that integrates sensory information into coherent perception. In ketamine research, this disconnection reduces functional connectivity within the brain's default mode network and increases cortical signal randomness, producing the characteristic feelings of detachment from self and environment.inferred
Why It Matters
The most explanatory model is the glutamate surge hypothesis: NMDA blockade silences inhibitory interneurons, which unleashes a burst of excitatory glutamate from pyramidal neurons. This burst drives rapid formation of new synaptic connections via BDNF release and mTOR pathway activation — the mechanism behind ketamine's rapid antidepressant effect.inferred
Du et al. (2022) provide the only direct molecular data for 2-FDCK, reporting changes in BDNF and related signaling proteins in the reward circuitry of rats that self-administered the compound.[7] These findings parallel ketamine's known effects on mesolimbic circuits and suggest conservation of downstream signaling consequences.
The most significant gap is the complete absence of binding affinity data — until someone measures how tightly 2-FDCK binds the NMDA receptor, its potency relative to ketamine remains unknown.[1][2] Whether the fluorine substitution changes receptor residence time could explain observed duration differences. Whether chronic use produces the severe bladder damage documented with ketamine remains among the most clinically urgent unanswered questions.[22]
Subjective Effects[edit]
The 2-FDCK experience builds gradually into a warm, layered dissociation — less abrupt than ketamine by most accounts, with a gentler onset curve that permits more psychological preparation at equivalent intensities. At lower doses, effects center on mild cognitive softening and perceptual shifts; at higher doses, the experience deepens into full disconnection from body and environment, including hole states. Set and setting strongly shape the qualitative character — calm, familiar environments favor introspective dissociation, while chaotic contexts increase the probability of agitation and dysphoria.
Within the dissociative class, 2-FDCK sits between Ketamine and deschloroketamine: slightly less potent and somewhat longer-lasting than ketamine with a smoother subjective quality, but shorter-acting and less sedating than DCK with a cleaner offset.
Effect Grid
At common doses (25–70 mg oral, 45–100 mg insufflated), the full dissociative experience emerges. Cognitive disconnection becomes pronounced — thoughts loop, fragment, or take on surreal associations. Depersonalization and derealization are typical, with the sense of inhabiting one's body becoming attenuated. Time distortion is significant, with minutes feeling stretched or compressed unpredictably. Visual distortions include environmental drifting, depth perception alteration, and dim visual patterning.
Physically, substantial analgesia develops alongside marked motor incoordination, nystagmus, and difficulty with speech. Tachycardia and mild hypertension are documented at these doses. Nausea occurs in a minority of users.
Ambulation is impaired. Users should remain seated or lying down. The experience requires 2–4 hours of commitment depending on route.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sensory deprivation · Music enhancement · Touch suppression · Depth perception distortion · Proprioceptive distortion · Vestibular distortion · Visual haze / noise · Dreaming enhancement · Auditory distortion · Auditory misinterpretation · Geometry · Peripheral vision distortion · Tracers · Visual drifting · After-images · Auditory enhancement · Auditory suppression · Visual morphing · Visual melting · Internal hallucinations · Visual processing suppression · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Auditory hallucinations · Visual scenery slicing
Proprioceptive distortion · Vestibular distortion · Visual haze / noise · Dreaming enhancement · Auditory distortion · Auditory misinterpretation · Geometry · Peripheral vision distortion · Tracers · Visual drifting · After-images · Auditory enhancement · Auditory suppression · Visual morphing · Visual melting · Internal hallucinations · Visual processing suppression · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Auditory hallucinations · Visual scenery slicing
Spontaneous body sensations · Bodily lightness · Body high · Body schema distortion · Muscle relaxation · Sedation · Tactile euphoria · Sexual arousal suppression · Bodily heaviness · Dry mouth · Heart rate perception changes · Nasal congestion · Physical fatigue · Pupil dilation · Stimulation · Nausea · Appetite suppression · Headache · Insomnia · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Wakefulness · Involuntary body movements · Restlessness · Trembling · Vomiting · Motor control enhancement · Bodily dissociation
Muscle relaxation · Sedation · Tactile euphoria · Sexual arousal suppression · Bodily heaviness · Dry mouth · Heart rate perception changes · Nasal congestion · Physical fatigue · Pupil dilation · Stimulation · Nausea · Appetite suppression · Headache · Insomnia · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Wakefulness · Involuntary body movements · Restlessness · Trembling · Vomiting · Motor control enhancement · Bodily dissociation
Immersion enhancement · Analysis suppression · Introspection enhancement · Thought deceleration · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Pattern recognition suppression · Conceptual thinking · Cognitive fatigue · Novelty enhancement · Openness enhancement · Thought disorganization · Creativity enhancement · Humor enhancement · Cognitive flexibility · Delusions of sobriety · Motivation suppression · Thought connectivity · Thought loops · Amnesia
Thought deceleration · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Pattern recognition suppression · Conceptual thinking · Cognitive fatigue · Novelty enhancement · Openness enhancement · Thought disorganization · Creativity enhancement · Humor enhancement · Cognitive flexibility · Motivation suppression · Thought connectivity · Thought loops · Amnesia
Emotional lability · Dysphoria
Social disconnection · Automaticity · Sociability suppression · Craving · Flow state · Compulsive behavior reduction · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Flow state · Compulsive behavior reduction · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Time cessation
Cessation · Entity contact · Near-death experience · Non-dual awareness · Transpersonal visions · Death-rebirth sequence
Transpersonal visions · Death-rebirth sequence
Timeline
First alerts emerge as a subtle cognitive shift — mild warmth, slight perceptual loosening, and an incipient sense of detachment from immediate surroundings.
Dissociative effects build progressively. Cognitive disconnection becomes apparent, analgesia develops, and spatial perception begins to soften. Mild nausea may occur during this phase.
Maximum dissociation. Depersonalization, derealization, and time distortion dominate. Motor coordination is significantly impaired, with nystagmus and speech difficulty common.
Dissociative intensity gradually diminishes. Cognitive function begins returning but remains loosened. Analgesia persists.
Effects taper toward baseline. Mild cognitive fog, residual analgesia, and slight motor incoordination may linger. Mood may be mildly elevated or subdued.
Residual cognitive softness and mild mood alteration may persist for several hours. Some users report improved mood or reflective clarity; others note fatigue or emotional flatness.
⚠ Do not drive or operate machinery for at least 6 hours after the last dose, as residual dissociative impairment and slowed reaction times may persist beyond subjective resolution.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · deschloroketamine · methoxetamine
Toxicity
No lethal dose has been established for 2-FDCK in any species.[2]
Acute Toxicity
In the largest reported clinical series, all 20 patients recovered with supportive care — but 5 experienced unconsciousness or convulsions.[15] Clinical presentations include impaired consciousness, agitation, hallucinations, rapid heart rate, and elevated blood pressure.[15][2] All documented fatalities occurred in polydrug settings, with respiratory depression as the cause.[7][8]
Cardiovascular Effects
Rapid heart rate and elevated blood pressure are consistently documented with acute use.[15][2] This makes 2-FDCK particularly risky for anyone with existing heart or blood pressure conditions.
Urological Toxicity
Chronic ketamine use causes severe bladder damage — progressive contraction, constant pain, and in severe cases irreversible loss of function.[19][20] 2-FDCK's structural similarity raises the same concern, though no 2-FDCK-specific bladder data have been published.inferred
Contamination
Seized samples have ranged in purity from 67% to 96%, with trace deschloroketamine contamination.[6] 2-FDCK has also been identified as an adulterant in samples sold as other substances.[21]
Psychological Risks
Acute effects can include agitation, hallucinations, and severe dissociative confusion.[15][2] One case of self-mutilation during intoxication has been documented.[7] By analogy to ketamine, repeated high-dose use carries risk of lasting cognitive impairment.inferred
Tolerance & Dependence
Tolerance builds with repeated use, with cross-tolerance expected across Ketamine, Deschloroketamine, and methoxetamine.[13] Clinical dependence has been documented in multiple countries, with one case confirmed by 9 months of hair analysis.[6][2] Preclinical evidence puts its abuse liability on par with ketamine.[13][18]
Withdrawal is primarily psychological — anxiety, irritability, sleep disturbance, cravings — without a physical syndrome or seizure risk.[22]
Drug Interactions
The highest-risk combinations are with other depressants — alcohol, GHB, GBL, and opioids each compound 2-FDCK's sedating effects and can cause breathing to stop.[7][8] All documented fatalities involved exactly this pattern.
Tramadol adds seizure risk through a separate mechanism.inferred Combining multiple dissociatives substantially elevates risk — 19 of 20 patients in the largest clinical series had co-exposure to at least one other ketamine-type drug.[15]
Contraindications
8 knownNo 2-FDCK-specific contraindication data exist — the following are inferred from its effect profile and analogy to ketamine.
- Heart conditions or high blood pressure — documented cardiovascular stimulation makes these contraindicated[15][2]
- History of psychotic disorders — glutamate-blocking drugs can trigger psychotic episodes inferred
- Pre-existing bladder conditions — structural similarity to ketamine makes this a relative contraindication[19]
- Respiratory compromise — all polydrug fatalities involved respiratory failure[8]
- Concurrent CNS depressants — absolute contraindication; every documented fatality involved polydrug combinations
Harm Reduction[edit]
Forms & Identification
2-FDCK powder is visually indistinguishable from ketamine and related compounds — reagent testing is essential for confirming identity. Batch purity ranges from 67% to 96%,[6] meaning two samples that look identical can differ significantly in potency. Start with a low test dose from any new batch to calibrate.
Guidelines
- Test every batch with reagent kits before use
- Start low with any new batch or unfamiliar source — purity varies widely
- Weigh doses with a milligram-precision scale; do not estimate by eye
- Allow full onset before redosing (60–90 minutes oral, 20–30 minutes insufflated)
- Have a sober sitter present at moderate-to-high doses
- Stay hydrated but do not overdrink — moderate fluid intake
- Eat lightly 2–3 hours before oral use to reduce nausea
- Avoid use on consecutive days; allow recovery time between sessions
- Monitor urinary symptoms with any pattern of repeated use
Set & Setting
2-FDCK impairs coordination, judgment, and spatial awareness in a dose-dependent way. Use in a safe, familiar environment away from heights, water, and traffic. A sober companion is strongly recommended at moderate-to-high doses. The gradual onset can encourage premature redosing — allow the full onset window before considering additional material.
Aftercare & integration. A dissociative afterglow can persist for hours to a day — a residual cognitive softness and mild emotional openness that fades gradually. During this period, avoid driving, operating machinery, or making significant decisions. Light food, hydration, and rest support recovery.
If the experience was intense — especially near hole states — allow time to process. Journaling, conversation with a trusted person, or integration-oriented therapy can help contextualize unusual perceptions. Persistent feelings of unreality or detachment lasting beyond 48 hours warrant professional consultation.
Recovery & Support
Compulsive daily use of 2-FDCK has been clinically documented, and dependence-related admissions have been reported across multiple countries. Professional support is available. Substance use counselors, addiction medicine specialists, and peer support groups — including ketamine-specific communities — can provide appropriate care. Withdrawal is primarily psychological — cravings, irritability, sleep disturbance — rather than physically dangerous.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: loss of consciousness, seizures or convulsions, severely slowed or stopped breathing, blue or grey lips, chest pain, or complete unresponsiveness go beyond uncomfortable dissociation and require immediate help.
Immediate steps:
- 1. Call emergency services
- 2. Place the person in the recovery position (on their side) if unconscious but breathing
- 3. Monitor breathing continuously — count breaths; below 10 per minute is critical
- 4. Do not leave the person alone
- 5. Do not induce vomiting
- 6. Do not restrain unless there is immediate danger of self-harm
What to tell the dispatcher: Name the substance (2-FDCK, fluoroketamine, or dissociative), the approximate amount and time taken, the route of administration, and current symptoms. Many jurisdictions have Good Samaritan laws that protect people who call for help during a drug emergency.
Legal Status[edit]
2-FDCK is internationally controlled under Schedule II of the 1971 Convention on Psychotropic Substances, following a WHO recommendation and a UN vote in March 2024.[2][4] This obligates all signatory states to implement domestic controls.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II, Convention on Psychotropic Substances 1971 | WHO ECDD recommendation October 2023; CND vote March 2024. Binding on all signatory states.[4] |
| United States | Schedule I (temporary) | DEA temporary placement announced January 20, 2026, effective February 19, 2026. Previously unscheduled at federal level.[5] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Prohibited as a psychoactive substance. Individual listing under the Misuse of Drugs Act 1971 has not been confirmed.citation needed |
| European Union | Detected in 22 Member States; controlled in at least 5 individually | Italy, Latvia, Sweden confirmed with individual controls; Belgium under blanket ban. International Schedule II now applies to all signatory states.[2] |
| Canada | Controlled under CDSA analogue provisions | Covered under Schedule II analogue provisions of the Controlled Drugs and Substances Act.citation needed |
| Netherlands | Banned | Specifically prohibited as of February 2026.citation needed |
| Japan | Individually controlled | National legislation in place prior to international scheduling.[2] |
| Sweden | Individually controlled | National controls in place prior to international scheduling.[2] |
| Australia | Scheduling status under review | Detected in Australian drug markets. Specific scheduling under the Poisons Standard (TGA Schedule 9) has not been confirmed.citation needed |
Legal status changes frequently. This information reflects known status as of early 2026 and is not legal advice. Verify local laws independently before traveling or purchasing.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · deschloroketamine · methoxetamine
Toxicity
No lethal dose has been established for 2-FDCK in any species, and no therapeutic index exists.[2]
Acute Toxicity
In the largest clinical series (20 patients), all recovered with supportive care, suggesting that acute intoxication at typical doses is survivable with medical attention.[13] However, 5 of 20 cases involved loss of consciousness or convulsions, indicating a potentially narrow margin between recreational and medically serious doses.
Clinical presentations include impaired consciousness, agitation, abnormal behavior, nystagmus, hallucinations, rapid heart rate, and elevated blood pressure.[13][2]
All documented fatalities have occurred in polydrug contexts. One death involved co-use with 3-MeO-PCE and was attributed to respiratory depression.[10] Two additional deaths were reported in polydrug settings, one with a very high blood concentration (5,885 µg/L).[9] No fatality has been attributed to 2-FDCK alone.
Cardiovascular Effects
Rapid heart rate and elevated blood pressure are consistently documented across clinical presentations and represent the primary acute cardiovascular risk.[13][2]
Urological Toxicity
Chronic ketamine use causes severe bladder damage — contracted bladder capacity, pain, frequent urination, blood in urine, and in severe cases irreversible bladder shrinkage.[22][23] The structural proximity of 2-FDCK to ketamine raises concern that chronic use may carry similar risk, though no published data on 2-FDCK-specific bladder effects exist.inferred
Contamination
Seized samples have shown purity variability (67–96%) with trace deschloroketamine contamination (0.4–0.6%).[8] 2-FDCK has also been identified as an adulterant in purported 3-MMC samples.[24]
Psychological Risks
Acute psychological adverse effects include agitation, abnormal behavior, hallucinations, and dissociative confusion.[13][2] One case of self-mutilation during intoxication has been documented.[9]
No data exist on 2-FDCK and persistent perceptual changes, psychosis precipitation, or long-term psychiatric outcomes. By analogy to ketamine, repeated high-dose use carries risk of lasting cognitive impairment and dissociative symptomatology.inferred
Tolerance & Dependence
Tolerance develops with repeated use. Cross-tolerance with other NMDA antagonists — including Ketamine, Deschloroketamine, and methoxetamine — is expected and supported by drug discrimination data showing full generalization between 2-FDCK and ketamine.[6]
Clinical dependence has been documented. Hair analysis of a chronic daily user confirmed sustained high concentrations spanning approximately 9 months.[8] Dependence-related clinical admissions have been reported across multiple countries.[2] The DEA cited sufficient abuse potential to warrant Schedule I placement.[5]
Preclinical evidence strongly supports abuse liability comparable to ketamine, including conditioned place preference, self-administration, and drug-seeking reinstatement at comparable doses.[6][7]
Withdrawal is expected to be primarily psychological — anxiety, irritability, sleep disturbance, cravings — without a prominent physical withdrawal syndrome or seizure risk.[25]
Drug Interactions
No 2-FDCK-specific interaction studies have been published. All assessments below are based on pharmacological class reasoning and analogy to ketamine.
The primary lethal mechanism is additive sedation and respiratory depression when combined with other depressants. All documented fatalities involved polydrug use.[9][10]
Alcohol, GHB, and GBL represent the highest-risk combinations. Each compounds the sedative effects of NMDA antagonism. GHB and GBL produce steep dose-response curves for respiratory depression, dangerously narrowing the safety margin.inferred
Opioids add respiratory depression through an independent mechanism — brainstem suppression stacked on top of dissociative sedation.inferred
Tramadol introduces seizure risk through its proconvulsant metabolite, creating an unpredictable interaction with NMDA antagonism.inferred
Multiple dissociatives combined substantially elevate risk. In the largest clinical series, 19 of 20 cases involved co-exposure to at least one other ketamine-type drug.[13]
Contraindications
8 knownNo 2-FDCK-specific contraindication data have been published. The following are inferred from its clinical effect profile and structural analogy to ketamine:
Heart conditions and high blood pressure — the documented acute cardiovascular stimulation (rapid heart rate, elevated blood pressure) makes these contraindicated.[13][2]
History of psychotic disorders — the documented psychotomimetic effects and established psychosis-precipitating potential of NMDA antagonists make this contraindicated.inferred
Pre-existing bladder conditions — the documented bladder toxicity of structurally related ketamine makes this a relative contraindication.[22]
Respiratory compromise — fatal outcomes in polydrug contexts involved respiratory depression.[10]
Concurrent use of CNS depressants — an absolute contraindication given that all documented fatalities involved polydrug combinations.
Harm Reduction[edit]
Forms & Identification
The structured data module above shows reagent results, physical forms, and common substitutions. 2-FDCK is visually indistinguishable from ketamine and several other arylcyclohexylamines in powder form, making reagent testing essential for confirming identity. Purity varies substantially between batches — forensic analyses have documented levels from 67% to 96%[8] — meaning two visually identical samples can differ significantly in potency. Start with a low test dose from any new batch to calibrate.
Guidelines
- Test every batch with reagent kits before use
- Start low with any new batch or unfamiliar source — purity varies widely
- Weigh doses with a milligram-precision scale; do not estimate by eye
- Allow full onset before redosing (60–90 minutes oral, 20–30 minutes insufflated)
- Have a sober sitter present at moderate-to-high doses
- Stay hydrated but do not overdrink — moderate fluid intake
- Eat lightly 2–3 hours before oral use to reduce nausea
- Avoid use on consecutive days; allow recovery time between sessions
- Monitor urinary symptoms with any pattern of repeated use
Set & Setting
2-FDCK produces dose-dependent impairment of coordination, judgment, and spatial awareness. Use in a safe, familiar environment with stable flooring and no access to heights, water, or traffic. A sober companion is strongly recommended at moderate-to-high doses, and essential at any dose approaching a hole state. The gradual onset can encourage premature redosing — allow the full onset window to pass before considering additional material.
Aftercare & integration. The dissociative afterglow can persist for hours to a day — a residual cognitive softness and mild emotional openness that fades gradually. During this period, avoid driving, operating machinery, or making significant decisions. Light food, hydration, and rest support recovery.
If the experience was psychologically intense — particularly at higher doses or in hole states — allow time to process. Journaling, conversation with a trusted person, or integration-oriented therapy can help contextualize unusual perceptions or insights. Persistent feelings of unreality or detachment lasting beyond 48 hours warrant professional consultation.
Recovery & Support
Compulsive daily use of 2-FDCK has been clinically documented, and dependence-related admissions have been reported in multiple countries. If use has become difficult to control, professional support is available. Substance use counselors, addiction medicine specialists, and peer support groups (including ketamine-specific communities) can provide appropriate care. Withdrawal is expected to be primarily psychological — cravings, irritability, sleep disturbance — rather than physically dangerous, but professional guidance improves outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: loss of consciousness, seizures or convulsions, severely slowed or stopped breathing, blue or grey lips, chest pain, or complete unresponsiveness go beyond uncomfortable dissociation and require immediate help.
Immediate steps:
- 1. Call emergency services
- 2. Place the person in the recovery position (on their side) if unconscious but breathing
- 3. Monitor breathing continuously — count breaths; below 10 per minute is critical
- 4. Do not leave the person alone
- 5. Do not induce vomiting
- 6. Do not restrain unless there is immediate danger of self-harm
What to tell the dispatcher: Name the substance (2-FDCK, fluoroketamine, or dissociative), the approximate amount and time taken, the route of administration, and current symptoms. Many jurisdictions have Good Samaritan laws that protect people who call for help during a drug emergency.
Legal Status[edit]
2-FDCK is internationally controlled under Schedule II of the 1971 Convention on Psychotropic Substances, following the WHO ECDD recommendation in October 2023[2] and the Commission on Narcotic Drugs vote in March 2024.[4] This obligates all signatory states to implement domestic controls. Prior to international scheduling, several jurisdictions had already individually controlled or captured the compound under blanket NPS legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II, Convention on Psychotropic Substances 1971 | WHO ECDD recommendation October 2023; CND vote March 2024. Binding on all signatory states.[4] |
| United States | Schedule I (temporary) | DEA temporary placement announced January 20, 2026, effective February 19, 2026. Previously unscheduled at federal level.[5] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Prohibited as a psychoactive substance. Individual listing under the Misuse of Drugs Act 1971 has not been confirmed.citation needed |
| European Union | Detected in 22 Member States; controlled in at least 5 individually | Italy, Latvia, Sweden confirmed with individual controls; Belgium under blanket ban. International Schedule II now applies to all signatory states.[2] |
| Canada | Controlled under CDSA analogue provisions | Covered under Schedule II analogue provisions of the Controlled Drugs and Substances Act.citation needed |
| Netherlands | Banned | Specifically prohibited as of February 2026.citation needed |
| Japan | Individually controlled | National legislation in place prior to international scheduling.[2] |
| Sweden | Individually controlled | National controls in place prior to international scheduling.[2] |
| Australia | Scheduling status under review | Detected in Australian drug markets. Specific scheduling under the Poisons Standard (TGA Schedule 9) has not been confirmed.citation needed |
Frequently asked questions
What is 2-Fluorodeschloroketamine?
2-Fluorodeschloroketamine is a synthetic dissociative of the arylcyclohexylamine class, differing from ketamine by a fluorine-for-chlorine substitution. First synthesized in 1987, it emerged on research-chemical markets around 2015 and was placed in UN Schedule II in 2024.
How long does 2-Fluorodeschloroketamine last?
Total duration by route of administration — Oral: 2.5 – 5 hours; Insufflated: 1.5 – 3 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 2-Fluorodeschloroketamine?
Psychedex publishes a dosage table for 2-Fluorodeschloroketamine on this page covering these routes of administration: oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 2-Fluorodeschloroketamine?
The highest-severity documented interactions for 2-Fluorodeschloroketamine: GHB, GBL (Lethal), Ibogaine (Lethal), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antihistamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 2-Fluorodeschloroketamine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 2-Fluorodeschloroketamine: tolerance builds moderate; full reset takes 10 days; cross-tolerance develops with ketamine, deschloroketamine, methoxetamine, phencyclidine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abcdLi F, Du H, Wu B, Wei J, Qiao Y, Lai M, Zhou W, Shen H, Wang Y, Xu P, Di B (2022) 2-Fluorodeschloroketamine has similar abuse potential as ketamine — Addiction Biology doi:10.1111/adb.13171